🔗 Read more: bit.ly/ONCOnews10D-03

#ONCOnews #OncoAlert #OncEd #OncologyNews #SurvivalBenefit #Immunotherapy #ClinicalTrials

Mitazalimab shows promising survival rates in cancer study - PharmaTimes Updated data from phase 2 study reveals survival benefit

#oncology #Mitazalimab #survivalrates #phase2study #survivalbenefit #AlligatorBioscience #phase2clincialtrial #OPTIMIZE1study #combinationtherapy #mFOLFIRINOX #metastaticpancreaticcancer #pancreaticcancer #pancreaticcancerpatients #clinicaltrials #drugdevelopment
pharmatimes.com/news/mitazal...